Giuliana Alimena

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann et al. · Blood · 2007 · 745 citations · Full text

Medicine, Oncology, Pharmacology +9

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

Sergio Amadori, Stefan Suciu, Dominik Selleslag et al. · Journal of Clinical Oncology · 2016 · 348 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia

CD Bloomfield, A.I. Goldman, Giuliana Alimena et al. · Blood · 1986 · 300 citations · Full text

Life Sciences, Genetics, Oncology +16

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

Fabio Efficace, Michele Baccarani, Massimo Breccia et al. · Blood · 2011 · 256 citations

Pharmacy, Oncology, Pharmacotherapy +15

Relative response of patients with myelodysplastic syndromes and other transfusion‐dependent anaemias to deferasirox (ICL670): a 1‐yr prospective study

John B. Porter, Renzo Galanello, Giuseppe Saglio et al. · European Journal Of Haematology · 2007 · 239 citations · Full text

Medicine, Hematology, Pharmacology +17